Compare
Compare archived captures
This view highlights text differences between two archived captures. It does not interpret meaning or provide guidance.
Descriptive changes only
This comparison highlights text changes between archived captures. It does not interpret the change or provide medical advice. For up-to-date recommendations, always consult the official source website.
Need to cite this comparison? See /cite.
Earlier capture
Biologics, radiopharmaceuticals and genetic therapies - Canada.ca
Apr 18, 2025
legacy-hc-2025-04-21
ID 202159
Later capture
Biologics, radiopharmaceuticals and genetic therapies - Canada.ca
Jan 2, 2026
hc-20260101
ID 429046
updated3 sections changed
3 sections changed0 added0 removed+4 / -3 linesChange ratio: 7%
--- +++ @@ -1,5 +1,8 @@ Biologics, radiopharmaceuticals and genetic therapies Current consultations+Consultation on Guidance Document: Information and Submission Requirements for Biosimilar Biologic Drugs+[2025-06-10]+Past consultations Consultation: Notice of intent to amend the regulations to address health product shortages in Canada [2024-06-25] Consultation on improving access to drugs and other health products in Canada@@ -10,7 +13,6 @@ [2016-04-15] Draft - Revised Guidance Document: Information and Submission Requirements for Subsequent Entry Biologics (SEBs) [2015-12-07]-Past consultations Consultation on the Draft Guidance Document: Harmonized requirements for the licensing of vaccines and guidelines for the preparation of an application [2015-06-03] Consultation on the Release of draft Part I: Health Professional Information and Part II: Scientific Information - Guidance Document: Product Monograph@@ -48,5 +50,4 @@ Additional resources Advisory Committees Page details-Date modified:-2025-04-16+2025-06-10